vimarsana.com

Page 3 - மருந்துகள் கட்டுப்படுத்தி ஜநரல் ஆஃப் இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India exempts global vax from clinical trials

Vaccine batch should be certified by national lab of country of origin.

United kingdomHimachal pradeshHaffkine biopharmaSandeep rathodAstrazeneca covishieldCentre onCentral drugs laboratoryNational control laboratoryController generalUse listingUk mhra and pmda japanRussia sputnikDrugs controller general of indiaCovid 19 vaccinesCovaxin haffkine biopharmaCongress mp shashi tharoor

Serum Institute seeks nod for licence to manufacture Sputnik V

Once the company gets permission, it will have to conduct clinical trials and if successful, the Serum Institute will become the seventh company to manufacture Sputnik V

Serum institute of indiaSerum instituteDrug controller generalSputnikv vaccineDrugs controller general of indiaSii approaches dcgiSii application for sputnikv vaccineSerum institute to manufacture sputnikv vaccineSputnikv vaccine covidSputnikv latest newsசீரம் நிறுவனம் ஆஃப் இந்தியாசீரம் நிறுவனம்மருந்து கட்டுப்படுத்தி ஜநரல்மருந்துகள் கட்டுப்படுத்தி ஜநரல் ஆஃப் இந்தியா

Moderna vaccine: Pfizer, Moderna vaccines may soon be available in India

The Drugs Controller General of India (DCGI) has done away with specific trials of COVID-19 vaccines that have been approved by other international regulatory bodies - a big move likely to clear the way for foreign vaccines like Pfizer and Moderna for the country s urgent requirement.

United kingdomHimachal pradeshCentral drugs laboratoryWorld health organisationDrugs controller generalEmergency useWorld healthNational control laboratorySummary lot protocolLot shallModerna vaccinePfizer vaccineVg somaniDrugs controller general of indiaஒன்றுபட்டது கிஂக்டம்கச ul லி

Hetero Biopharma gets nod for Sputnik phase-3 trials

The RDIF has signed agreements with several companies to manufacture Sputnik V in India — Virchow Biotech (up to 200 million doses per year) Gland Pharma (252 million doses) and Stelis Biopharma (200 million doses).

Himachal pradeshStelis biopharmaRussia direct investment fundCentral drugs laboratoryHyderabad based hetero biopharmaDrugs controller generalVirchow biotechGland pharmaDrugs controller general of indiaSputnikv vaccine dosesHetero biopharmaகச ul லிஇமாச்சல் பிரதேஷ்ரஷ்யா நேரடி முதலீடு நிதிமைய மருந்துகள் ஆய்வகம்மருந்துகள் கட்டுப்படுத்தி ஜநரல்

Zydus Cadila seeks DCGI nod for human trials of Covid-19 antibody cocktail

Zydus is the only Indian company which claims to have developed a neutralising monoclonal antibodies (mAbs) based cocktail for the treatment of COVID 19

Zydus cadilaEli lillySharvil patelDrug administrationDrug controller generalManaging directorDrugs controller general of indiaZydus cadila covid 19 drugZydus cadila covid 19 antibody drugZydus cadila covid 19 antibody cocktailZydus cadila monoclonal covid 19 antibodiesZydus cadila latest covid 19 drugஜய்துச் காடிலாஎலி லில்லிஷார்வில் படேல்மருந்து கட்டுப்படுத்தி ஜநரல்

vimarsana © 2020. All Rights Reserved.